Correlation between COVID-19 and hepatitis B: A systematic review

He, Yanfei; Jiang, Zhigang; Ni, Wei; Bian, Ning; Ren, Jun

doi:10.3748/wjg.v28.i46.6599

Cited by 10 publications

(12 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although several studies have investigated the association between CHB and COVID‐19 outcomes, the findings are inconsistent. Multiple factors, including the number of patients, difference in SARS‐CoV‐2 variants included, and criteria for patients matching, may result in the inconsistencies 21,22 . In this study, using the existing CHB cohort, we recruited a relatively large number of CHB and COVID‐19 co‐infection patients over a short period.…”

Section: Discussionmentioning

confidence: 99%

“…variants included, and criteria for patients matching, may result in the inconsistencies. 21,22 In this study, using the existing CHB cohort, we recruited a relatively large number of CHB and COVID-19 coinfection patients over a short period. Using a PSM to eliminate the confounding factors, we revealed that pre-existing CHB was associated with milder symptoms and shorter disease course, compared to the non-CHB group.…”

Section: Tdf and Etv Did Not Differ Significantly In Affecting Sympto...mentioning

confidence: 99%

“…Recently, studies have also shown that anti‐HBV treatments, such as tenofovir disoproxil fumarate (TDF) and entecavir (ETV), may be associated with a reduced risk of SARS‐CoV‐2 infection and may have a positive impact on recovery from COVID‐19 19,20 . Nevertheless, these controversial conclusions indicate a need for further investigation into the underlying interactions between HBV and SARS‐CoV‐2 coinfection 21–23 …”

Section: Introductionmentioning

confidence: 99%

“…19,20 Nevertheless, these controversial conclusions indicate a need for further investigation into the underlying interactions between HBV and SARS-CoV-2 coinfection. [21][22][23] In December 2022, China abandoned its "dynamic zero-COVID" policy and lifted most of the restrictive measures. This policy change led to a rapid surge in Omicron variant infections among the Chinese population within a span of just 2 months around the 2023 new year.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Alleviated symptoms of SARS‐CoV‐2 Omicron variant infection in chronic hepatitis B patients with immune control

Liu,

Zhang,

Kong

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

The impact of hepatitis B virus (HBV) infection on the progression of coronavirus disease 2019 (COVID‐19) disease remains controversial. We aimed to investigate whether pre‐existing chronic HBV (CHB) infection and therapy with anti‐HBV nucleos(t)ide analogs (NAs) influence the clinical presentation of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron variant infection. In this study, clinical information was collected via a questionnaire from patients with COVID‐19, and their clinical symptoms were quantitatively assessed for comparative analyses. Additionally, hepatitis B‐related laboratory data were collected for CHB patients. Propensity score matching (PSM) was used to minimize confounding biases. A total of 785 patients with COVID‐19 were included in the cohort, of which 387 were identified as being infected with CHB infection and they were categorized as being in the immune control or clearance phase. After PSM, the CHB group (n = 222) had a shorter duration of fever and disease course, milder clinical symptoms, and lower incidence of pneumonia than the non‐CHB group (n = 222) after Omicron variant infection (p < 0.05). After the adjustment of confounding factors, CHB patients showed a lower risk of prolonged fever, severe clinical symptoms, and pneumonia (p < 0.05). However, there were no statistically significant differences in the clinical symptoms and incidence of pneumonia between CHB patients who received and did not receive NAs, or CHB patients who received tenofovir disoproxil fumarate and entecavir (p > 0.05). In conclusion, our findings suggest that the crosstalk of anti‐HBV immunity may contribute to the alleviated symptoms of SARS‐CoV‐2 Omicron variants infection in the CHB patients, independent of anti‐HBV NA therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Tdf and Etv Did Not Differ Significantly In Affecting Sympto...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Alleviated symptoms of SARS‐CoV‐2 Omicron variant infection in chronic hepatitis B patients with immune control

Liu,

Zhang,

Kong

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…The case of HBV chronic infected patients under treatment is of interest. The severity of COVID-19 seems not to be affected by chronic HBV infection [ 69 ]. On the other side, patients with chronic B hepatitis have a higher risk of developing COVID-19 vs. healthy subjects [ 70 ].…”

Section: Resultsmentioning

confidence: 99%

Liver Damage and COVID-19: At Least a “Two-Hit” Story in Systematic Review

Montori

Baroni

Santori³

et al. 2023

CIMB

View full text Add to dashboard Cite

COVID-19 pandemic waves have hit on our lives with pulmonary and, also, gastrointestinal symptoms. The latter also includes acute liver damage linked to direct SARS-CoV-2 action and/or drug-induced (DILI) in the frame of pre-existing chronic liver disease. We aimed to review literature data regarding liver damage during COVID-19. We conducted a systematic search on the main medical databases for original articles, reviews, meta-analyses, randomized clinical trials and case series using the following keywords and acronyms and their associations: liver disease, COVID-19, acute liver damage, drug-induced liver injury, antivirals. Acute liver damage due to SARS-CoV-2 infection is common among COVID-19 patients and is generally self-limiting. However, chronic hepatic diseases, such as metabolic-associated fatty liver disease (MAFLD), are associated with a less favorable prognosis, especially when alkaline phosphatases show a significant rise. Pathophysiology of COVID-19 liver damage is multifaceted and helps understand differences in liver derangement among patients. Thus, early recognition, monitoring and treatment of liver damage are crucial in these patients. In the frame of a not-ending pandemic sustained by SARS-CoV-2, it is crucial to recognize acute hepatic decompensation due to the virus and/or drugs used for COVID-19 treatment.

show abstract

Research on Design Method for Online Panoramic Tourist Website Based on AHP-QFD

Ren

Fang

et al. 2023

Lecture Notes in Computer Science

View full text Add to dashboard Cite

Correlation between COVID-19 and hepatitis B: A systematic review

Cited by 10 publications

References 145 publications

Alleviated symptoms of SARS‐CoV‐2 Omicron variant infection in chronic hepatitis B patients with immune control

Alleviated symptoms of SARS‐CoV‐2 Omicron variant infection in chronic hepatitis B patients with immune control

Liver Damage and COVID-19: At Least a “Two-Hit” Story in Systematic Review

Research on Design Method for Online Panoramic Tourist Website Based on AHP-QFD

Contact Info

Product

Resources

About